The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Clovis Oncology; Merck; Roche/Genentech
Consulting or Advisory Role - Abbvie; Agenus; Alkermes; AstraZeneca; Clovis Oncology; Deciphera; Eisai/BMS; Genelux; Genmab; GlaxoSmithKline; ImmunoGen; Merck; Novocure; OncoQuest; OncXerna Therapeutics; Regeneron; Roche/Genentech; VBL Therapeutics
Research Funding - AstraZeneca; Clovis Oncology; Genelux; Genmab; ImmunoGen; Merck; Roche/Genentech
 
Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; Amgen; Arquer Diagnostics; AstraZeneca; Celsion; Clovis Oncology; Corcept Therapeutics; Eisai; Elevar Therapeutics; Genentech/Roche; GOG Foundation; ImmunoGen; InxMed; Iovance Biotherapeutics; Johnson & Johnson/Janssen; Merck; Mersana; Myriad Genetics; Novartis; Novocure; Regeneron; Roche; Rubius Therapeutics; Seagen; Sumitomo Dainippon Pharma Oncology/BBI; Takeda; Tarveda Therapeutics; Tesaro/GSK; Toray Industries
Research Funding - Abbvie; Agenus; Ajinomoto; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; EMD Serono; Ergomed; Genentech/Roche; Genmab; GOG Foundation; ImmunoGen; Inc Research; inVentiv Health; Iovance Biotherapeutics; Johnson & Johnson/Janssen; Ludwig Institute for Cancer Research; Merck; Mersana; New Mexico Cancer Care Alliance; Novocure; PRA Health Sciences; Regeneron; Seagen; Sorrento Therapeutics; Stemcentrix; Sumitomo Dainippon Pharma Oncology/BBI; Tesaro/GSK; TRACON Pharma; VentiRx; Yale University
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
 
Matthew A. Powell
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline/Tesaro; GOG partners; Roche/Genentech; Seagen; Tesaro
Research Funding - GlaxoSmithKline/Tesaro (Inst)
 
Sakari Hietanen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD
Speakers' Bureau - AstraZeneca; GlaxoSmithKline
 
Robert L. Coleman
No Relationships to Disclose
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Oleksandr Zub
No Relationships to Disclose
 
David M. O'Malley
No Relationships to Disclose
 
Lucy Gilbert
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Merck/Eisai
Consulting or Advisory Role - GlaxoSmithKline; Merck
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Esperas Pharma (Inst); Immunogen (Inst); IMV (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Tesaro/GSK (Inst)
 
Iwona Podzielinski
No Relationships to Disclose
 
Roberto Angioli
No Relationships to Disclose
 
Dana Meredith Chase
Honoraria - AstraZeneca/Merck; Eisai; Genmab/Seattle Genetics; Merck; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca/Merck; Immunogen; Tesaro/GSK
Speakers' Bureau - AstraZeneca/Merck; Eisai; Genmab/Seattle Genetics; Roche; Tesaro/GSK
Research Funding - Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Tesaro/GSK
 
Dirk Bauerschlag
Leadership - Ago Study Group
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD
Research Funding - GlaxoSmithKline (Inst)
 
Destin Black
Research Funding - GlaxoSmithKline (Inst)
Other Relationship - GOG Foundation; Trials365
 
Annemarie Thijs
No Relationships to Disclose
 
Sudarshan Sharma
No Relationships to Disclose
 
Michael A. Gold
No Relationships to Disclose
 
Kari L Ring
No Relationships to Disclose
 
Zangdong He
Employment - GlaxoSmithKline
 
Shadi Stevens
Employment - GlaxoSmithKline
 
Brian M. Slomovitz
Consulting or Advisory Role - Agenus; AstraZeneca; Eisai; EQRx; Genentech; GlaxoSmithKline; GOG Foundation; Incyte; Lilly; Merck; Myriad Genetics; Nuvation Bio; Onconova Therapeutics; Onconova Therapeutics; Regeneron
 
Mansoor R. Mirza
Leadership - Karyopharm Therapeutics; Sera Prognostics
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - Allarity Therapeutics; AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Oncology Venture; Roche; Sotio; Takeda; Zai Lab
Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer; Sotio
Research Funding - Apexigen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Tesaro (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup